Company intelligence / Profile preview
Alesta Therapeutics
Leiden, Netherlandsalestatherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead program ALE1 is progressing through GLP toxicology studies with plans to initiate clinical studies in 2025. ALE2 is in development for CMT disease.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small moleculesoral small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Alesta Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alesta Therapeutics.